Medtronic has signalled its intent to get to the sharp end in a significant market, by acquiring a majority of the shares of Biostar, which will assume the distribution of Medtronic products in Turkey formerly distributed by Medicall Biomedikal A.S. The end result is a complicated affair, with Medicall and Medtronic collaborating to manage Turkish distribution, including the additional resource brought in through the Biostar acquisition.
Medicall has been a Medtronic distributor in Turkey since 2003, handling Medtronic’s Cardiac Rhythm Disease Management, Atrial Fibrillation Solutions, Structural Heart and Renal Denervation product lines. What will happen now is that Biostar will assume this responsibility. Medicall will also own some of Biostar and indeed Medicall’s previous CEO, Ayhan Öztürk will assume the responsibility of Medtronic Turkey. Atilla Küçükyalçin, who has served as Vice President Sales & Marketing of Medicall, will lead the CardioVascular Group (CVG) of Medtronic Turkey. Their responsibilities will include the activities of Biostar.
Medtronic will be expecting its collaboration with Medicall, embodied in their joint ownership of Biostar, will bring it certain benefits in what is a substantial market. By having a firmer hand on its Turkish distribution it will see reduced barriers to treatment, and the sharing of experience and expertise will open up new opportunities for training and education of healthcare professionals to better meet the needs of physicians and patients in Turkey. One’s assuming it’ll benefit by enjoying all the marginal income for its products too.
What will actually happen on the ground then, is that Medicall will render certain services to Biostar to ensure a smooth transition of the business, including transferring 85 of its 130 staff.
In the meantime Medicall will continue to distribute its non-Medtronic product lines.
“In key emerging markets like Turkey, creative collaborative ventures like these can help us address the barriers to treatment that patients face today,” said Majid Kaddoumi, Vice President and Managing Director of Medtronic Middle East, Turkey and Africa. “We believe this new relationship will bring us closer to the healthcare system in Turkey and will help increase access to available therapies, improve outcomes through our Academia programs, and optimize cost and efficiency for hospitals, physicians, patients and payers.”
“After more than 10 years of working with Medtronic, we look forward to this new relationship and believe that with our ambitious plans, this alignment will have a very positive impact on the local medical community,” said Necmettin Yilmaz, President of Ankor Holding, parent company of Medicall.
Source: Medtronic, Inc.